Almirall: Lebrikizumab cada cuatro semanas mantiene un aclaramiento duradero de la piel en... 29/09/2022 Healthcare Access to innovation Innovative drugs Corporate Almirall ha anunciado recientemente nuevos resultados completos de los estudios de fase 3 en monoterapia para la... Partners - Almirall
Laminar Pharma obtains FDA Fast Track designation for LAM561 for the treatment of glioblas... 26/09/2022 Healthcare Innovative drugs Laminar Pharma has been granted by the US FDA with a Fast-Track designation for the investigation of LAM561 for the... Partners - Laminar Pharma
BIAT GROUP has just signed a new development and licence contract with a Top Vet leader fo... 20/09/2022 Healthcare Innovative drugs Antibiotic resistance Climate change Animal health La Sociedad ha firmado un contrato de desarrollo y licencia con una compañía líder multinacional del sector veterinario... Partners - Biotechnology Assets
Affirma Biotech closes a seed round of 600.000 EUR to continue with the proof of concept o... 20/09/2022 Access to innovation Innovative drugs Corporate Affirma Biotech, a start-up based in Sant Pau’s Hospital, was incorporated in September 2020 by Maribel Berges and Joan... Partners - AFFIRMA BIOTECH
#NewMember | "AseBio is both the place to meet other companies in the industry and the voi... 29/09/2022 Access to innovation Innovative drugs Meet Affirma Biotech, our new member. We talked to Maribel Berges, CEO of the company. AseBio - AFFIRMA BIOTECH
Minoryx presenta la solicitud de autorización de comercialización de su fármaco leriglita... 14/09/2022 Access to innovation Innovative drugs Corporate La adrenoleucodistrofia ligada al cromosoma X (X-ALD) es una enfermedad minoritaria y neurodegenerativa para la cual no... Partners - Minoryx Therapeutics
Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against varian... 15/06/2022 Access to innovation Drug discovery Innovative drugs Next-generation booster vaccine candidate delivers immune boost in adults primed with mRNA vaccines; with a stronger... Partners - SANOFI
#NewMember | "AseBio will enable us to provide differential and disruptive value" 19/05/2022 Healthcare Innovative drugs Meet Mikrobiomik, our new member. We talk with Juan Basterra, CEO of the company AseBio - Mikrobiomik
Peaches Biotech publishes positive “in vivo” results of its drug PRS CK STORM 18/05/2022 Healthcare Innovative drugs Personalized medicine Advanced therapies The results show the high efficacy and safety of PRS CK STORM as a medicine to prevent and treat the cytokine storm... Partners - PEACHES BIOTECH S.L.
PharmaBoardoom points out VIVEbiotech as one of the ten Spanish Biotechs to watch in 2022 21/04/2022 Rare diseases Innovative drugs Personalized medicine Advanced therapies PharmaBoardroom, a leading British media specialized in the health sector, has published an article in which it... Partners - VIVEbiotech
